ATE471315T1 - Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten - Google Patents
Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheitenInfo
- Publication number
- ATE471315T1 ATE471315T1 AT02773770T AT02773770T ATE471315T1 AT E471315 T1 ATE471315 T1 AT E471315T1 AT 02773770 T AT02773770 T AT 02773770T AT 02773770 T AT02773770 T AT 02773770T AT E471315 T1 ATE471315 T1 AT E471315T1
- Authority
- AT
- Austria
- Prior art keywords
- 17beta
- androgen
- piperidine
- treatment
- type
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 2
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 title 1
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 title 1
- VNRJGEMERJZKLQ-UHFFFAOYSA-N 2-piperazin-1-ylacetamide Chemical compound NC(=O)CN1CCNCC1 VNRJGEMERJZKLQ-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33006601P | 2001-10-17 | 2001-10-17 | |
| PCT/US2002/032979 WO2003033487A1 (en) | 2001-10-17 | 2002-10-15 | Piperidine- and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE471315T1 true ATE471315T1 (de) | 2010-07-15 |
Family
ID=23288179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02773770T ATE471315T1 (de) | 2001-10-17 | 2002-10-15 | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6969718B2 (de) |
| EP (1) | EP1436281B1 (de) |
| JP (1) | JP4309761B2 (de) |
| CN (1) | CN1571782A (de) |
| AR (1) | AR036812A1 (de) |
| AT (1) | ATE471315T1 (de) |
| CA (1) | CA2463626C (de) |
| DE (1) | DE60236743D1 (de) |
| ES (1) | ES2347643T3 (de) |
| MX (1) | MXPA04003611A (de) |
| PE (1) | PE20030705A1 (de) |
| WO (1) | WO2003033487A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60332862D1 (de) | 2002-11-18 | 2010-07-15 | Schering Corp | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen |
| DE60323765D1 (de) | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
| GB0314733D0 (en) * | 2003-06-24 | 2003-07-30 | Glaxo Group Ltd | Medicaments |
| TW200528110A (en) * | 2003-12-17 | 2005-09-01 | Schering Corp | Pharmaceutical compositions |
| CA2548309A1 (en) * | 2003-12-22 | 2005-07-14 | Amgen Inc. | Aryl sulfonamide compounds and uses related thereto |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| CA2606004A1 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| SG11201510251TA (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
| WO2014207309A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1 |
| JP6523461B2 (ja) | 2014-12-23 | 2019-06-05 | フォレンド ファーマ リミテッド | １７β−ＨＳＤ１−阻害剤のプロドラッグ |
| JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| CN115716860A (zh) | 2017-06-08 | 2023-02-28 | 佛恩多制药有限公司 | 15β-[3-丙酰氨基]-取代的雌-1,3,5(10)-三烯-17-酮及17-肟 |
| MX2020006219A (es) | 2017-12-15 | 2020-12-03 | Inthera Bioscience AG | Derivados de 1-piperidinocarbonilmetil)-2-oxopiperazina para tratar cancer. |
| KR20210114390A (ko) | 2018-12-05 | 2021-09-23 | 포렌도 파마 리미티드 | 17-hsd1의 억제제로서의 피라졸 고리와 위치 16(17)에서 축합된 에스트라-1,3,5(10)-트리엔 화합물 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
| DE2304154A1 (de) * | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | Verfahren zur herstellung von substituierten piperazin- bzw. homopiperazinderivaten |
| DE2304153A1 (de) * | 1973-01-29 | 1974-08-01 | Ichthyol Ges Cordes Hermanni & | Substituierte piperazin- und homopiperazinderivate |
| AU594309B2 (en) | 1984-08-02 | 1990-03-08 | Fernand Labrie | Pharmaceutical composition for combination therapy of hormonedependent cancers |
| ES2077675T3 (es) | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
| KR920703063A (ko) | 1989-07-07 | 1992-12-17 | 원본미기재 | 양성 전립선 비대증의 예방 및/ 또는 치료를 위한 복합요법 |
| CA2062792C (en) | 1989-07-07 | 2006-03-21 | Fernard Labrie | Treatment of androgen-related diseases |
| IL99320A (en) * | 1990-09-05 | 1995-07-31 | Sanofi Sa | Arylalkylamines, their preparation and pharmaceutical preparations containing them |
| CZ280532B6 (cs) * | 1990-10-10 | 1996-02-14 | Schering Corporation | Pyridinové a pyridin-N-oxidové deriváty diaryl-methyl-piperidinů nebo piperazinů, jejich použití a způsob jejich přípravy, farmaceutický prostředek je obsahující |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| JPH07505393A (ja) * | 1992-03-27 | 1995-06-15 | シェリング・コーポレーション | 非橋渡しビスアリールカルビノール誘導体，組成物および使用法 |
| WO1994026767A1 (en) | 1993-05-17 | 1994-11-24 | Endorecherche Inc. | Improved antiandrogens |
| WO1994010165A1 (en) | 1992-10-28 | 1994-05-11 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| CA2150951A1 (en) | 1992-12-14 | 1994-06-23 | Angus Murray Macleod | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
| AU680020B2 (en) | 1993-06-07 | 1997-07-17 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin antagonists |
| IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
| DE69504300T2 (de) | 1994-01-13 | 1999-04-29 | Merck Sharp & Dohme | Gem-bissubstituierte azazyclische tachykinin-antagonisten |
| JP3038016B2 (ja) * | 1995-04-07 | 2000-05-08 | シェーリング コーポレイション | ファルネシルタンパク質トランスフェラーゼを阻害する、カルボニルピペラジニルおよびカルボニルピペリジニル化合物 |
| US5795894A (en) * | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| US5719156A (en) * | 1995-05-02 | 1998-02-17 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5696267A (en) * | 1995-05-02 | 1997-12-09 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5688960A (en) * | 1995-05-02 | 1997-11-18 | Schering Corporation | Substituted oximes, hydrazones and olefins useful as neurokinin antagonists |
| US5654316A (en) * | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
| US5892039A (en) * | 1995-08-31 | 1999-04-06 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| DE19614204A1 (de) * | 1996-04-10 | 1997-10-16 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US5691362A (en) * | 1996-06-05 | 1997-11-25 | Schering-Plough Corporation | Substituted benzene-fused hetero- and carbocyclics as nuerokinin antagonists |
| US5789422A (en) * | 1996-10-28 | 1998-08-04 | Schering Corporation | Substituted arylalkylamines as neurokinin antagonists |
| US5968929A (en) * | 1996-10-30 | 1999-10-19 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5945428A (en) * | 1996-11-01 | 1999-08-31 | Schering Corporation | Substituted oximes, hydrazones and olefins as neurokinin antagonists |
| US5783579A (en) * | 1996-12-20 | 1998-07-21 | Schering Corporation | Spiro-substituted azacyclic-substituted piperazino derivatives as neurokinin antagonists |
| US6063926A (en) * | 1998-11-18 | 2000-05-16 | Schering Corporation | Substituted oximes as neurokinin antagonists |
| CN1181069C (zh) * | 1998-12-23 | 2004-12-22 | 先灵公司 | 新的法尼基蛋白转移酶抑制剂 |
| US6204265B1 (en) * | 1998-12-23 | 2001-03-20 | Schering Corporation | Substituted oximes and hydrazones as neurokinin antagonists |
| WO2000043008A1 (en) | 1999-01-25 | 2000-07-27 | Smithkline Beecham Corporation | Anti-androgens and methods for treating disease |
| AU1413301A (en) * | 1999-11-17 | 2001-05-30 | Sumitomo Pharmaceuticals Company, Limited | Diabetic remedy containing dipiperazine derivative |
| PT1423381E (pt) * | 2001-09-06 | 2007-04-30 | Schering Corp | Inibidores de 17-b-hidroxiesteróide-desidrogenase do tipo 3 para o tratamento de doenças dependentes de androgénio |
-
2002
- 2002-10-15 EP EP02773770A patent/EP1436281B1/de not_active Expired - Lifetime
- 2002-10-15 AT AT02773770T patent/ATE471315T1/de not_active IP Right Cessation
- 2002-10-15 JP JP2003536227A patent/JP4309761B2/ja not_active Expired - Fee Related
- 2002-10-15 ES ES02773770T patent/ES2347643T3/es not_active Expired - Lifetime
- 2002-10-15 CA CA2463626A patent/CA2463626C/en not_active Expired - Fee Related
- 2002-10-15 CN CNA02820557XA patent/CN1571782A/zh active Pending
- 2002-10-15 PE PE2002001016A patent/PE20030705A1/es not_active Application Discontinuation
- 2002-10-15 US US10/271,358 patent/US6969718B2/en not_active Expired - Fee Related
- 2002-10-15 MX MXPA04003611A patent/MXPA04003611A/es active IP Right Grant
- 2002-10-15 DE DE60236743T patent/DE60236743D1/de not_active Expired - Lifetime
- 2002-10-15 WO PCT/US2002/032979 patent/WO2003033487A1/en active Application Filing
- 2002-10-15 AR ARP020103851A patent/AR036812A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04003611A (es) | 2004-07-30 |
| DE60236743D1 (de) | 2010-07-29 |
| CA2463626A1 (en) | 2003-04-24 |
| JP2005506356A (ja) | 2005-03-03 |
| AR036812A1 (es) | 2004-10-06 |
| US20030232837A1 (en) | 2003-12-18 |
| ES2347643T3 (es) | 2010-11-03 |
| EP1436281B1 (de) | 2010-06-16 |
| CA2463626C (en) | 2011-05-24 |
| CN1571782A (zh) | 2005-01-26 |
| US6969718B2 (en) | 2005-11-29 |
| EP1436281A1 (de) | 2004-07-14 |
| WO2003033487A1 (en) | 2003-04-24 |
| PE20030705A1 (es) | 2003-08-21 |
| JP4309761B2 (ja) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE350375T1 (de) | 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen | |
| ATE471315T1 (de) | Piperidin- und piperazinacetamide als inhibitoren der 17beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE602004018338D1 (de) | Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund | |
| ATE458753T1 (de) | Methoden der verhinderung und behandlung der alzheimer'schen krankheit | |
| CY2014031I2 (el) | Τροποποιημενα 2’ και 3’-νουκλεοζιτικα προφαρμακα για θεραπεια μολυνσεων απο flaviviridae | |
| DE602004010407D1 (de) | Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden | |
| DE60216122D1 (de) | Cysteinprotease-hemmer mit 2-cyano-4-amino-pyrimidinstruktur und cathepsin-k-hemmender wirkung zur behandlung von entzündungen und anderen erkrankungen | |
| DE60223694D1 (de) | Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums | |
| DE60108080D1 (de) | Aminopyrazolderivate zur behandlung von übergewicht und anderen gesundheitsstörungen | |
| ATE299890T1 (de) | Inhibitoren von gamma-secretase | |
| DE60223715D1 (de) | Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten | |
| DE60122196D1 (de) | Synergistische antioxidans-kombination von delta tocols und polyphenolen | |
| ATE434444T1 (de) | Vorbeugung und behandlung von amyloidogenischen krankheiten | |
| DE60132777D1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
| ATE481093T1 (de) | Vervendung von dexrazoxane in der prävention und behandlung der alzeheimer-krankheit | |
| EE200200442A (et) | Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks | |
| DE50306850D1 (de) | Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen | |
| MA28176A1 (fr) | Inhibiteurs de la forme mutante du kit | |
| ATE362928T1 (de) | 2-(1h-indazol-6-ylamino)- benzamid-verbindungen als protein kinase inhibitoren und deren verwendung zur behandlung von ophthalmischen krankheiten | |
| DE60214542D1 (de) | Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks | |
| DE60106968D1 (de) | Kombination von gaba agonisten und sorbitol dehydrogenase inhibitoren | |
| DE60134009D1 (de) | Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose | |
| ATE303379T1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| ATE469886T1 (de) | 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |